Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macitentan vs standard of care in pediatric pulmonary arterial hypertension
2023-509845-10-00Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, open-label trial of macitentan in pulmonary arterial hypertension (PAH) (3 arms), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Trough plasma concentrations of macitentan and ACT-132577 at Week 12 (subjects ≥2 years, macitentan arm) and Trough plasma concentrations of macitentan and ACT-132577 at Week 4 (subjects <2 years, macitentan). Started Aug 2024; status: completed.
02
Drugs
macitentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2023-509845-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509845-10-00.